The incidence in Northern and Western Europe is over 200 / 100,000, and the rate of the newly detected PCa is continuously increasing. (1) The PCa screening is one of the most controversial topics of the urological field. Pathological digital rectal examination (DRE) and prostate-specific antigen (PSA) levels give suspect of PCa. The exact diagnosis and the decision of the further PCa-therapy depend on the histopathological verification of an adenocarcinoma in prostate biopsy (PB) samples or operative specimens. The management of patients receiving a non-operative therapy (for example high intensity focused ultrasound (HIFU) or brachytherapy alone) depends on the PSA value and greatly on the PB Gleason Score (GS). (4) Patients, who had general sextant prostate biopsy, have up to a 1-in-3 chance to have a significant upgrading (SU) in the final pathological report. (5,6)
Recent clinical study has investigated whether an extended PB scheme is associated with an improvement in the accuracy between the PB GS and radical prostatectomy (RP) pathology. Over and above it tried to identify probable preoperative variables that stratified patients likely to harbor SU.
The data of the five hundred and thirty-eight patients diagnosed with PCa, who underwent RP and exhibited a SU were retrospectively reviewed. The patients were divided into 3 groups: Group-A, who underwent a 6-core (lateral) PB (36%), Group-B who underwent a 12-core (lateral-medial) PB (28.9%) and Group-C (34.9%) who underwent an 18-core (lateral-mediolateral-medial) PB.
The interpretational bias of the pathologists is a very sensitive and complex issue. The exact interpretation of the biopsy specimen requires a deep experience. That is why all PB cores were analyzed by a highly experienced single pathologist. A multivariate analysis was conducted (PSA level, clinical T-Stage, volume of the prostate gland and duration from PB to RP).
The conclusion of the study is that an extended prostate biopsy scheme is associated with a significant improvement in the accuracy between the PB GS and RP pathology. Prostate volume >35 ml in patients who undergo a 6- or 12-core prostate biopsy is the only preoperative variable that stratifies patients likely to harbor SU.
Sandor Poth MD, Department of Urology, Malteser Kliniken Rhein Ruhr, Krefeld, Germany
Vahudin Zugor PD MD, Department of Urology, University Hospital of Cologne, Cologne, Germany
Read the Abstract
- M. Arnold, H. E. Karim-Kos, J. W. Coebergh, G. Byrnes, A. Antilla, J. Ferlay, A. G. Renehan, D. Forman and I. Soerjomataram: Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur. J. Cancer, vol. 51, no. 9, pp. 1164–87, Jun. 2015.
- L. Evangelista, A. Briganti A, S. Fanti, S. Joniau S, S. Reske, R. Schiavina, C. Stief, G.N. Thalmann and M. Picchio: New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol., vol. 70, no.1, pp. 161-75, Jul. 2016
- V. Zugor, R. Kühn, K. Engelhard, S. Poth, M.M. Bernat, D. Porres and A.P. Labanaris: The Value of Endorectal Magnetic Resonance Imaging of the Prostate in Improving the Detection of Anterior Prostate Cancer. Anticancer Res., vol. 36, no.8, pp. 4279-83, Aug. 2016.
- H.Tsumura, T. Satoh, H. Ishiyama, K. Tabata, S. Komori, A. Sekiguchi, M. Ikeda, S. Kurosaka, T. Fujita, M. Kitano, K. Hayakawa and M. Iwamura: Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer. J Contemp Brachytherapy,vol. 8, nr. 2, pp. 95-103, Apr. 2016.
- C. R. King, J. E. McNeal, H. Gill and J. C. Presti: Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys., vol. 59, no. 2, pp. 386–91, Jun. 2004.
- M. R. Cooperberg, J. M. Broering, M. S. Litwin, D. P. Lubeck, S. S. Mehta, J. M. Henning and P. R. Carroll: The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J. Urol., vol. 171, no. 4, pp. 1393–401, Apr. 2004.